Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) announced it has received approval from Nasdaq to transfer the listing of its common stock from the Nasdaq Capital Market to the Nasdaq Global Select Market. Trading on the higher tier is expected to begin at the open of market on March 3, 2026, under the existing ticker symbol "TNXP." The move reflects the company's compliance with the Nasdaq Global Select Market's more stringent financial and corporate governance requirements and is expected to enhance institutional visibility, liquidity and broader market recognition. Management described the uplisting as an important milestone as the company continues to focus on growth and shareholder value creation.
Tonix Pharmaceuticals is a fully-integrated, commercial-stage biotechnology company focused on central nervous system (CNS) and immunology treatments in areas of high unmet medical need. TONMYA(TM) (cyclobenzaprine HCl sublingual tablets 2.8mg), the Company's recently approved flagship medicine, is the first new treatment for fibromyalgia in more than 15 years. Tonix's CNS commercial infrastructure supports its marketed products, including its acute migraine products, Zembrace(R) SymTouch(R) and Tosymra(R). Tonix is maximizing the science behind TONMYA in Phase 2 clinical trials to evaluate its potential in major depressive disorder and acute stress disorder.
In addition, the company's CNS portfolio includes TNX-2900, which is Phase 2 ready for the treatment of Prader-Willi syndrome, a rare disease. Tonix is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection. Tonix's product development candidates are investigational new drugs or biologics; their efficacy and safety have not been established and have not been approved for any indication.
The Nasdaq Global Select Market listing represents a significant corporate achievement that typically signals to investors that a company meets higher financial standards and governance practices. For biotechnology companies like Tonix, this transition can facilitate greater analyst coverage, inclusion in more institutional portfolios, and potentially lower capital costs for future growth initiatives. The company's diverse pipeline addressing CNS disorders and immunological conditions positions it to potentially benefit from increased market attention following the uplisting.
The latest news and updates relating to TNXP are available in the company's newsroom at https://ibn.fm/TNXP. The press release announcing the Nasdaq listing approval can be viewed at https://ibn.fm/uDmmW. For biotechnology investors, the uplisting represents a maturation milestone that may increase trading liquidity and potentially reduce volatility, while for patients, Tonix's continued focus on CNS and immunology treatments addresses significant unmet medical needs across multiple conditions.
